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Case Report 
 
 
Sustained Remission in a Case of Lupus Nephritis 
with Cyclosporin Therapy 
 
Malik Anas Rabbani, Syed Mansoor Ahmad Shah, Aasim Ahmad 
 
Department of Medicine, Aga Khan University Hospital,  
Stadium Road, Karachi, Pakistan 
 
ABSTRACT. Systemic lupus erythematosus (SLE) in severe form still presents a major 
therapeutic challenge. Aggressive treatment of severe renal lesions has improved the 
prognosis of renal disease over the last decade. However, this benefit is quite frequently 
offset by the side effects and toxicity of the treatment. Moreover, the disease may appear to 
be poorly responsive to treatment with steroids and cytotoxic drugs. We report a case of 
lupus nephritis that relapsed despite having adequate steroid and cytotoxic therapy, but later 
was successfully treated with cyclosporin. Fifteen months after discontinuing the treatment 
with cyclosporin, the patient continued to remain in remission. 
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Introduction 
 
  Systemic lupus erythematosus (SLE) in 
severe form still presents a major therapeutic 
challenge. Renal involvement in SLE is 
variable; some patients have minimal 
clinical and histological involvement, while 
others have fulminant renal failure and 
severe proliferative renal lesions on biopsy.1  
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The World Health Organization (WHO) 
classification,2 which defines six major 
patterns of renal involvement, has greatly 
helped to study lupus nephritis. Trans-
formation from one pattern of lupus 
nephritis to another may occur.3 The 
optimal treatment of lupus nephritis varies 
with the type of disease. Aggressive 
immunosuppression is required for the 
more severe renal lesions such as diffuse or 
more severe focal proliferative glomerulo-
nephritis (GN) and  severe and progressive 
membranous GN (WHO Classes III, IV and 
V) as these lesions are at high risk for 
progressing to renal failure.4 Aggressive 
treatment of  the severe renal lesions has 
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 improved the prognosis of renal disease 
over the last decade. However, this benefit 
is quite frequently offset by the side effects 
and toxicity related to drugs.5 Moreover, 
disease may itself  be poorly responsive to 
treatment with steroids and cytotoxic drugs. 
  Cyclosporin A (CSA) is used as a corner 
stone in the prevention of graft rejection in-
patients who receive organ transplants. It 
has also been used in various autoimmune 
disorders including systemic lupus erythe-
matosus (SLE) because of its selective 
immunosuppressive effect. 
  We report here a case of lupus nephritis, 
which had frequently relapsed despite high 
dose steroids and cyclophosphamide and 
later was successfully managed with CSA 
based therapy. 
 
Case Report 
 
  A sixteen year old boy was admitted at the 
Aga Khan University Hospital with a one 
week history of high grade fever associated 
with chills and rigors, arthralgias involving 
hands, feet, knee and ankle joints and 
generalized purpuric rash. On examination, 
the pulse was 110/min, blood pressure 140/90 
mm Hg, respiratory rate 27/min and tempe-
rature 39°C. Chest examination revealed 
bilateral pleural effusions. Abdominal 
examination revealed hepatosplenomegaly 
without ascites. Mild pedal edema was 
noted. 
  Laboratory investigations revealed hemo-
globin of 102 gm/L, WBC 1.6 × 109/L, 
platelets 2.8 × 109/L,  ESR 61 mm/hour.  
 
 
 
 
Figure 1. The renal biopsy  showing large hypercellular glomerulus with lobular capillary tufts. The 
capillary lumina are obliterated by endocapillary cell proliferation and leukocytic infiltration. The tubules 
show vacuolar changes and the interstitium is slightly edematous (H & E Stain, Magnification x 200). 
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 Serum creatinine and electrolytes were 
within normal range. Serum C3 was 0.123u 
(N-0.5-0.9), serum C4 < 0.05u, anti (ds) 
DNA 2451 IU (Range 0-6 IU) and ANA 
strongly +ve. Liver function tests, proth-
rombin time and activated thrompoplastin 
time were normal. Chest x-ray confirmed 
the presence of bilateral pleural effusions. 
Urinalysis revealed +3 protein and micro-
scopic hematuria. 24-hour urine specimen 
revealed creatinine clearance of 98 ml/min 
and proteinuria of 3.6 gm/day. Renal biopsy 
was consistent with WHO class IV histo-
logical pattern, Figure 1. Immunoflou-
rescence of the renal biopsy revealed 
immunoglobulin deposits of IgG, IgM, IgA, 
C3 and C4.  
  The patient was treated with pulse 
methylprednisolone one gram/day for three 
days followed by oral steroids (1 mg/kg of 
body weight) and Azathioprine (1.5 mg/kg 
of body weight). The blood counts returned 
to normal values within a week and the 
proteinuria decreased from 3.6 gm/day to 
158 mg/day over the following three months. 
In the next six months the proteinuria 
relapsed twice despite the oral steroids and 
azathioprine. Each episode was treated with 
pulse methylprednisolone to which the patient 
responded well with protein excretion 
decreasing to less than 500 mg/day. 
Subsequently, the patient had a third relapse 
with proteinuria of 5 grams/day. At this 
point, oral cyclophosphamide (1.5 mg/kg of 
body weight) was substituted for azathio-
prine. This resulted in marked improvement 
as the protinuria disappeared. In order to 
avoid the risk of gonadal toxicity, cyclo-
phosphamide was withdrawn after 12 weeks 
and the patient was maintained on oral 
steroids and azathioprine. Unfortunately, 
proteinuria relapsed within three months 
after discontinuing the cyclophosphamide. 
Cyclosporin was then added along with 
steroids, which resulted in gradual improve-
ment over the following three months and 
the proteinuria decreased to less than 100 
mg/day. During the first three month of 
CSA therapy, the drug was given in a dose 
of 3 mg/kg of body weight and the whole 
blood CSA level was maintained between 
120-180 ng (radioimmune assay (RIA) with 
monoclonal antibodies). Cyclosporin was 
continued for further six months in a dose 
of 1.5-2 mg/kg of body weight and during 
this period  the whole blood CSA level was 
maintained between 120-150 ng (RIA with 
monoclonal antibodies). CSA was withdrawn 
gradually over the following few weeks. 
Fifteen months after withdrawal of all the 
treatment the patient continued to be 
proteinuria free with creatinine clearance of 
124 ml/min. 
 
Discussion 
 
  Lupus nephritis is a very complex auto-
immune renal disease. Successful treatment 
remains challenging due to lack of under-
standing of the underlying mechanisms and 
multiple symptoms ranging from skin 
rashes to glomerulonephritis. B cell hyper-
proliferation is characteristic of active SLE, 
which results in raised levels of circulating 
immunoglobulins and wide spread deposition 
of immune complexes in various tissues.6 
Several inflammatory and cell growth 
modifying processes also contribute to 
tissue destruction. 
  Lupus nephritis may run an extremely 
variable course and though specific therapy 
is not required in mild cases, a careful 
surveillance is required to detect  possible 
transformation to a  more severe disease 
state and flare ups.3 Vigorous treatment 
should be started early in patients with 
more severe forms of lupus nephritis that 
show active lesion in the  renal biopsy such 
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 as glomerular cell proliferation, necrosis, 
crescent formation, significant subendothelial 
immune complex deposition and inflam-
mation.7 Therapeutic modalities currently 
employed in lupus nephritis include oral 
corticosteroids, high dose pulse steroid 
therapy, cytotoxic drugs like cyclophos-
phamide and azathioprine, used either 
singly or in combination with steroids. 
Other therapeutic approaches such as 
mycophenolate mofetil and Tacrolimus  
have been used in the treatment of severe 
and difficult cases of SLE and have been 
shown to prolong life span, reduce 
proteinuria and prevent progression to 
nephropathy.8,9 Intravenous immunoglobulins 
and monoclonal antibodies have also been 
used in experiments, but their efficacy was 
modest.10,11 Plasma exchange therapy has 
been used for bulk depletion of immuno-
reactants. However, multicentre studies 
have confirmed no additional role of plasma 
exchange therapy in combination with 
cytotoxics when compared with sole short-
term use of cytotoxics in terms of patient 
survival, frequency of renal failure and 
other complications.12 Total lymphoid 
radiation has been claimed to be effective in 
some cases of refractory  lupus nephritis, a 
practical perspective on this form of 
immunosuppressive therapy has yet to be 
developed.13  
  Cyclosporin A (CSA) is a highly lipo-
philic cyclic peptide with 11 amino-acids. It 
blocks IL-2 synthesis by preventing 
transcription of IL-2 gene. Key steps are 
binding of CSA to a specific immuno-
phillin, blocking calcineurin and preventing 
the transcription of the gene of IL-2.14 
Studies have shown that CSA is  effective 
in reducing the activity of SLE and in 
controlling changes in clinical and 
laboratory parameters associated with 
disease especially in patients with poor 
response to conventional regimens.15 The 
overall clinical benefit is usually observed 
within 2-4 months of CSA therapy. 
Therefore, prolonged treatment should be 
aimed at consolidating rather than 
achieving further improvement.16 A large 
single center, prospective randomized study 
published from Italy evaluated disease 
activity according to systemic lupus activity 
measure (SLAM Score) in 27 patients who 
completed at least 24 months of treatment 
with CSA. It confirmed that the mean 
disease activity score  could significantly be 
reduced in terms of stabilizing renal 
function, reducing proteinuria, and 
normalizing leukopenia and thrombo-
cytopenia after six months of CSA therapy. 
This result was maintained through out the 
study.16 
  However, the use of CSA is limited 
mainly by its tendency to induce hyper-
tension and nephrotoxicity as well as the 
tendency to relapse  after discontinuing the 
treatment.16 Despite this, we believe that the 
use of CSA still needs to be further 
evaluated as an alternative to cyclophos-
phamide in the management of lupus in 
young patients, especially in pregnant 
females in view of its established safety 
concerning teratogenicity,17 or as  a second 
line agent for patient whose condition is 
poorly responsive or less tolerant to more 
conventional therapy. Prognosis and overall 
success certainly varies widely among 
geographically and racially diverse 
populations.18 
  We reported a case of lupus nephritis that 
relapsed despite having adequate steroid 
and cytotoxic therapy, but later was 
successfully treated with cyclosporin. 
Fifteen months after discontinuing the 
treatment with cyclosporin, the patient 
continued to remain in remission. 
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